5 Stocks Jensen Huang’s Company is Betting On

3. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a biotech company that combines multiple areas like medicine, engineering, data science, and automation. The purpose of these efforts is to revolutionize and industrialize the process of drug discovery. With the backing of Jensen Huang and co, one can assume there is something special about this company and that its efforts have a higher chance of success compared to others doing similar innovations.

The company’s pipeline of drugs includes RC-617, a treatment for advanced solid tumors. The solid tumor market is expected to grow to $375 billion by 2034 and with the positive phase 1 results, RXRX is set to penetrate that market soon. The phase 2 data for REC-994, a treatment for Cerebral Cavernous Malformation, is also set to be released soon.

The risk of the next phases of these innovative medical treatments may not necessarily be positive, but it is the management and the tradition of innovation that provides the value here and investors should see the bigger picture rather than test phase data.